F-Star Therapeutics - der Star am Pharma Himmel

Hi all, checkt F-Star Therapeutics ab. Gemerged mit Spring Bank Pharmaceuticals im November 2020 - riesen Potenzial
F-star is a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of F-star’s innovative tetravalent mAb2 bispecific antibodies.

With four distinct binding sites in a natural human antibody format, F-star believes its proprietary technology will overcome many of the challenges facing current immuno-oncology therapies, because of the strong pharmacology enabled by tetravalent bispecific binding.

F-star’s vision is to transform the treatment of cancer through the development of clinically differentiated and well tolerated mAb2 bispecific antibodies, which are designed to address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.

F-star’s leadership team has decades of combined experience in pharma and biotech. Together they have successfully brought 20 drugs to market.

https://investors.f-star.com/

 

https://www.fiercebiotech.com/biotech/...17-5m-upfront-1-35b-biobucks  

Zahlen für Q3/21

• Umsatz 1 Mio. $
• Verlust 11 Mio. $
• Cash 71 Mio. $
• MK 118 Mio. $

https://investors.f-star.com/news-releases/...-2021-financial-results

Sehr interessantes Biotech.

 

MK 106 Mio. $, das Chancen-Risiko Verhältnis sieht vom aktuellen Niveau aus betrachtet attraktiv aus.  

Merck KGaA übt eine weitere Lizenz-Option aus

"Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all future development and commercialization costs and will pay future success-based milestones and royalties on any net sales, resulting from programs covered by the agreement."

https://investors.f-star.com/news-releases/...-kgaa-darmstadt-germany

 

MK 88 Mio. $, den Cashbestand zum 31.12 schätze ich auf ~60 Mio. $. Die Cashreichweite schätze ich auf 6 Quartale. In meinen Augen sind das aktuell Kaufkurse.  

Mk 76 Mio. $, ich gebe prinzipiell wenig auf Analystenkursziele und Einschätzungen, aber falls jemand Wert darauf legt:

• 7 Coverings --> 7x kaufen
  
• das niedrigste Kursziel liegt bei 15$
  

https://www.wsj.com/market-data/quotes/FSTX/research-ratings

 

MK 64 Mio. $, nicht mehr weit bis zum Cashniveau  

Zahlen für 2021

• Umsatz 21 Mio. $
  
• Verlust 31 Mio. $
  
• Cash 79 Mio. $
  
• MK 62 Mio. $
  

Multiple Clinical Program Updates Expected in 2022

https://investors.f-star.com/news-releases/...1-financial-results-and

 

Zahlen für Q1/22

• Umsatz 2,6 Mio. $
  
• Verlust 12 Mio. $
  
• Cash 69 Mio. $
  
• MK 54 Mio. $
  

-  Four Clinical Readouts Anticipated Throughout 2022

https://investors.f-star.com/news-releases/...-2022-financial-results

 

Übernahme

• invoX (Tochter von Sino Biopharmaceutical) will FSTX in einem All-Cash-Deal übernehmen
  
• Bewertung 161 Mio. $ bzw. 7,12$ Cash je Aktie
  

https://investors.f-star.com/news-releases/...ics-inc-pioneering-next